AI medication adherence sensor market seen doubling by 2030

The Business Research Company says the global market for AI-enhanced medication adherence sensors will rise from $1.96 billion in 2025 to $4.75 billion by 2030, driven by remote patient monitoring, AI analytics and digital health adoption. North America held the largest share in 2025 as the report highlights growing use in chronic care, clinical trials and elderly patient management.

Why it matters: - AI-enhanced medication adherence sensors are becoming a bigger part of remote care and medication management. - The market is growing fast because healthcare systems want better adherence tracking, fewer missed doses and more data for clinicians. - The report points to expanding use in chronic disease care, clinical trials and elderly patient support.

What happened: - The Business Research Company released a 2026 report on the global AI-enhanced medication adherence sensor market. - The report estimates the market at $1.96 billion in 2025 and $2.34 billion in 2026. - It projects the market will reach $4.75 billion by 2030. - The release was dated July 25, 2026, from London.

The details: - The market is forecast to grow at a 19.7% CAGR in the historical period cited by the report. - The report forecasts a 19.4% CAGR through 2030. - Growth drivers include medication non-adherence, rising chronic disease rates, digital health adoption, improved clinical trial monitoring and wearable sensor innovation. - Future demand is tied to remote patient monitoring, AI-powered adherence analytics, value-based care, aging populations and the digitization of pharmaceutical trials. - The report highlights real-time medication tracking, chronic disease compliance tools, remote monitoring, elderly-focused medication management and clinical trial adherence monitoring as key trends. - AI-enhanced medication adherence sensors use algorithms to monitor how patients take medications and generate real-time insights for intervention. - The sensors track adherence patterns and send data to clinicians to support timely action without in-person visits. - North America held the largest market share in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The Business Research Company also offers a free sample of the report through this sample download. - The full report is available here.

Between the lines: - The report frames adherence sensors as part of a broader shift toward connected care, where monitoring moves outside hospitals and clinics. - The emphasis on value-based care suggests buyers are looking for tools that can show measurable outcomes, not just collect data. - England’s virtual ward rollout, cited in the release, shows how remote monitoring infrastructure is already creating demand for connected patient tools. - In March 2025, the Parliamentary Office of Science and Technology said England had 12,825 virtual ward beds in use, equal to 20 beds per 100,000 GP-registered individuals, with 76.2% occupancy and 9,767 patients served.

What's next: - The market is expected to keep expanding as hospitals, trial sponsors and health systems adopt more remote monitoring workflows. - The report expects more product development around real-time tracking, AI analytics and patient-specific adherence support. - The Business Research Company says its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards and market hotspot infographics.

The bottom line: - AI-enhanced medication adherence sensors are moving from niche monitoring tools to a growth market tied to remote care, digital trials and chronic disease management.